Tormere Analytics
OverviewStock ResearchChartsPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Articles
Pricing
Privacy PolicyTerms of Service

RVMD

$206.64+0.36%website ↗⬇ financials (.py)

Revolution Medicines, Inc.

Market Cap
$43.9B
Live price × shares (2026-09-17)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
1.38
60mo monthly vs SPY
P/E (TTM)
N/M
Price / TTM net income
P/S (TTM)
—
Price / TTM revenue
P/B
16.9
Price / stockholders equity
EV/EBITDA
—
TTM
Price Chart
Loading…

Signals

Insider Velocity
13.2x
selling
Congress
—
recent trades
Short Volume
56%
W/W -5.6pp

Market & Alt Data

News
15
recent articles
Activist
—
none active
Analyst Consensus
Strong Buy
28 analysts
Velocity Score
13.19x
Sell Rate (90d)
4228.71/mo
Sell Baseline
943.84/mo
Unique Sellers (90d)
9
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-09-292026-10-01Sandler Alan B.Chief Development OfficerSale6,309$202.14$1.28M52.6KView
2026-09-252026-09-29Cislini JeffSVP & General CounselSale765$207.32$159K51.8KView
2026-09-252026-09-28Mancini AnthonySee RemarksSale3,121$200.54$626K39.8KView
2026-09-242026-09-28Mancini AnthonySee RemarksSale587$200.00$117K39.8KView
2026-09-222026-09-24ANDERSON ELIZABETH MDirectorSale10.1K$193.04$1.96M4,333View
1–5 of 42
1 / 9

Reporting Insiders

  • Alan B. Sandler
    Chief Development Officer
    7 transactions · last 2026-09-29
  • Jeff Cislini
    SVP & General Counsel
    10 transactions · last 2026-09-25
  • Anthony Mancini
    See Remarks
    11 transactions · last 2026-09-25
  • Elizabeth M. Anderson
    Director
    5 transactions · last 2026-09-22
  • Jack Anders
    Chief Financial Officer
    3 transactions · last 2026-09-16
  • Stephen Michael Kelsey
    See Remarks
    11 transactions · last 2026-09-16
  • Margaret A. Horn
    Chief Operating Officer
    2 transactions · last 2026-09-16

Recent News

How Revolution Medicines Inc - Ordinary Shares (RVMD) Affects Rotational Strategy Timing
Stock Traders Daily · 2026-10-03
Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold
SeekingAlpha · 2026-10-03
Revolution Medicines (RVMD) Could Be 8% Overvalued As FTSE All World Inclusion Draws Focus
Simply Wall Street · 2026-10-02
Revolution Medicines (RVMD) counsel Jeff Cislini sold 765 shares at $207.3201 each under a trading plan.
Stock Titan · 2026-09-29
6,000 shares from exercised options are listed for an officer’s proposed sale at Revolution Medicines (RVMD).
Stock Titan · 2026-09-29
Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
Yahoo · 2026-09-28
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318
Benzinga · 2026-09-28
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Yahoo · 2026-09-28
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
Yahoo · 2026-09-25
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Yahoo · 2026-09-25
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target
Benzinga · 2026-09-24
Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?
Yahoo · 2026-09-23
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?
Yahoo · 2026-09-23
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE
Yahoo · 2026-09-22
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
Yahoo · 2026-09-22

Informational purposes only, not investment advice.

Revolution Medicines, Inc. (RVMD)

tormere.com/research/RVMD · generated 2026-10-05

$206.64
+0.36%
General Information
Price$206.64
Change+0.36%
Market Cap$43.9B
SectorHealth Care
IndustryBiotechnology
ExchangeNasdaq
Beta (raw, 60mo vs SPY)1.38
Signals
Insider Velocity13.2x selling
Congress Trades—
  • Mark A. Goldsmith
    Director & See Remarks
    20 transactions · last 2026-09-16
  • Lorence H. Kim
    Director
    14 transactions · last 2026-09-08
  • Sushil Patel
    Director
    8 transactions · last 2026-06-29
  • Jack Anders
    Chief Financial Officer
    5 transactions · last 2026-06-24
  • Margaret A. Horn
    Chief Operating Officer
    4 transactions · last 2026-06-17
    • Short Volume
    56% of daily vol
    Conviction Score20/100
    Analyst ConsensusSB 10 · B 16 · H 2 · S 0 · SS 0
    Price Chart (1 Year)
    2025-10-062026-10-02$221.15$46.57
    Recent Insider Activity (Form 4) — Last 5
    DateInsiderTypeSharesValue
    2026-09-29Sandler Alan B.S301$61,621.44
    2026-09-29Sandler Alan B.S1,199$244,484.97
    2026-09-29Sandler Alan B.S1,000$202,812.7
    2026-09-29Sandler Alan B.S1,609$324,573.76
    2026-09-29Sandler Alan B.S2,200$441,801.36
    Recent News
    • How Revolution Medicines Inc - Ordinary Shares (RVMD) Affects Rotational Strategy Timing — Stock Traders Daily · 2026-10-03
    • Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold — SeekingAlpha · 2026-10-03
    • Revolution Medicines (RVMD) Could Be 8% Overvalued As FTSE All World Inclusion Draws Focus — Simply Wall Street · 2026-10-02
    • Revolution Medicines (RVMD) counsel Jeff Cislini sold 765 shares at $207.3201 each under a trading plan. — Stock Titan · 2026-09-29
    • 6,000 shares from exercised options are listed for an officer’s proposed sale at Revolution Medicines (RVMD). — Stock Titan · 2026-09-29

    Tormere — informational purposes only, not investment advice.

    Factor Profile

    Pro
    Pro feature

    Fama-French factor analysis is available on the Pro plan.

    Upgrade to Pro →